We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Effect of Single Dose Paracetamol on the Lower Airways of Asthmatic and Healthy Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01073748
Recruitment Status : Unknown
Verified January 2011 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Recruiting
First Posted : February 23, 2010
Last Update Posted : January 25, 2011
Information provided by:
Tel-Aviv Sourasky Medical Center

Brief Summary:

Asthma is a common inflammatory airway disease. Several researches have demonstrated a possible connection between asthma and exposure to paracetamol.

Our hypothesis is that even a single dose of paracetamol is sufficient to cause a measurable change in lung functions.

This trial aims to identify a possible effect of single dose paracetamol on lower airway function.

Condition or disease Intervention/treatment
Asthma Drug: paracetamol

Detailed Description:

Asthma is a common inflammatory airway disease and its prevalence is on the rise all around the world, Most significantly in children under 5 years.

Paracetamol is one of the most common drugs used with children at thus age groups and several studies have proved a causative connection between exposure to paracetamol and asthma prevalence as well as other allergic conditions.

The mechanism is presumably by reduction of glutathione level, resulting in oxidative burst and formation of reactive oxygen species (ROS).

In addition, paracetamol maybe directly cytotoxic to pneumocytes if given in overdose.

The goal of this research is to identify and quantify the effect of single dose of paracetamol on lung functions of asthmatic and healthy subjects.

The study group will include 40 children aged 7-16 years, who are known to have asthma and a control group of 20 healthy children.

The children will be randomized to receive a dose of paracetamol or placebo, and lung functions will be measured by both spirometry and Fraction of expired Nitric Oxide (FeNO) test.

Each child will receive both paracetamol and placebo, randomly in to consecutive tests, thus children will serve as their own control.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Official Title: The Effect of Paracetamol on Lower Airway Obstruction in Asthmatic Versus Non Asthmatic Children
Study Start Date : March 2010
Estimated Primary Completion Date : March 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: asthmatic subjects
Asthmatic children will be randomly exposed to paracetamol and placebo consecutively and their lung functions will be blindly compared.
Drug: paracetamol
single dose of paracetamol 15mg/kg.
Other Names:
  • Acetaminophen
  • Acamol
Healthy children
Children with no asthma as control group.
Drug: paracetamol
single dose of paracetamol 15mg/kg.
Other Names:
  • Acetaminophen
  • Acamol

Primary Outcome Measures :
  1. A measurable change in lung functions in response to paracetamol exposure. [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   7 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • age: 7-16 years
  • research group: children who have been diagnosed as asthmatic according to the American thoracic society (ATS) criteria
  • control group: children who are not known to have asthma

Exclusion Criteria:

  • paracetamol sensitivity
  • children with any kind of chronic disease (except asthma)
  • children with non asthma related chronic lung disease
  • acute asthma attack
  • children on systemic steroids

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01073748

Contact: Ruth Soferman, M.D 972-3-6975691 ruthso@tasmc.health.gov.il
Contact: Assaf Tsivion, M.D 972-52-7360333 assaft@hotmail.com

Tel Aviv Sourasky Medical Center Recruiting
Tel Aviv, Israel
Sub-Investigator: Assaf Tsivion, M.D         
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Principal Investigator: Ruth Soferman, M.D TASMC

Responsible Party: Dr. Ruth Soferman, Tel-Aviv Sourasky Medical Center, Israel, Tel-Aviv Sourasky Medical Center, Israel
ClinicalTrials.gov Identifier: NCT01073748     History of Changes
Other Study ID Numbers: TASMC-10-RS-422-CTIL
First Posted: February 23, 2010    Key Record Dates
Last Update Posted: January 25, 2011
Last Verified: January 2011

Keywords provided by Tel-Aviv Sourasky Medical Center:
Lung function

Additional relevant MeSH terms:
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs